Early Menopausal Hormone Therapy May Reduce Heart Disease Risk, Study Suggests
New research indicates that initiating menopausal hormone therapy (MHT) during perimenopause or early postmenopause could significantly lower a woman's risk of cardiovascular disease. The protective effect was most pronounced when therapy began within 10 years of menopause onset.
What's new
A recent study published in JAMA Internal Medicine sheds new light on the relationship between menopausal hormone therapy (MHT) and cardiovascular disease risk. The research suggests that women who begin MHT during perimenopause or early postmenopause may experience a notable reduction in their risk of developing cardiovascular disease [1]. This finding builds upon existing knowledge that women generally face an elevated risk of heart disease after menopause, partly due to declining estrogen levels and other physiological changes [1].
The study's key finding indicates that starting hormone therapy during these earlier stages of the menopause transition could decrease cardiovascular disease risk by 22% compared to women not undergoing such therapy. The most significant protective effect, a 27% lower risk, was observed in women who initiated MHT within 10 years of their menopause onset. Interestingly, the study also highlighted a particularly strong benefit for Black women, showing a 49% reduction in cardiovascular disease risk when they started hormone therapy [1].
The science behind it
The researchers utilized 20 years of health data from over 2,700 women participating in the Study of Women’s Health Across the Nation (SWAN) project. Participants included women who reported menopause-related vasomotor symptoms, such as hot flashes and night sweats, and had no prior diagnosis of heart disease. They also self-reported their use of hormone therapy [1].
Previous studies have established that women's risk for cardiovascular disease increases after menopause. This is attributed to various factors, including reduced estrogen levels, which play a role in cardiovascular health, as well as changes in blood vessel stiffness, cholesterol profiles, and overall metabolism [1]. While earlier research has explored the potential of MHT to mitigate heart disease risk, much of it focused on women already well into postmenopause. This new study specifically aimed to investigate the impact of MHT initiation timing, particularly during perimenopause and early postmenopause, when hormonal fluctuations and symptoms are prominent [1].
By analyzing this extensive dataset, the study was able to observe the long-term cardiovascular outcomes in relation to when MHT was started. The findings suggest a 'window of opportunity' where MHT may be most effective in conferring cardiovascular benefits, aligning with the idea that early intervention during the hormonal transition could be crucial [1].
What it means in practice
For individuals navigating the menopause transition, these findings underscore the importance of discussing treatment options with healthcare providers, particularly regarding the timing of menopausal hormone therapy. The study implies that initiating MHT closer to the onset of menopause, specifically within 10 years, might offer the most substantial cardiovascular protection [1].
This research could influence clinical guidelines and patient-doctor conversations about MHT, moving towards a more individualized approach based on a woman's menopausal stage and individual risk factors. The observed stronger protective effect among Black women also highlights the potential for MHT to address health disparities in cardiovascular disease risk within different racial and ethnic groups [1].
However, it is important to remember that MHT is not a universal solution and involves a careful consideration of benefits and risks for each individual. Decisions about hormone therapy should always be made in consultation with a healthcare professional who can assess a woman's overall health, medical history, and specific symptoms [1].
Caveats
While this study provides valuable insights, it is important to consider its limitations. The research relied on self-reported data for both menopausal symptoms and hormone therapy use, which can introduce recall bias. Additionally, observational studies, like this one, can identify associations but cannot definitively prove cause and effect. There may be other unmeasured factors that influence both the decision to use MHT and cardiovascular outcomes [1].
The study also focused on women experiencing vasomotor symptoms, meaning the findings may not be directly generalizable to all women undergoing menopause, particularly those without such symptoms. Furthermore, while the study identified a stronger effect in Black women, further research is needed to understand the specific mechanisms behind this difference and to confirm these findings across diverse populations [1].
Future research, including randomized controlled trials, would be beneficial to further elucidate the optimal timing, duration, and specific formulations of MHT for cardiovascular protection, as well as to confirm the findings related to racial differences in response [1].
References · 1
- [1]Menopause: Early HRT start may lower heart disease risk by 27%Medical News Today · 2026